ZAGAM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZAGAM (ZAGAM).
Sparfloxacin, a fluoroquinolone antibiotic, inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby blocking DNA replication and transcription.
| Metabolism | Sparfloxacin is metabolized primarily via glucuronidation by UGT1A1 and UGT1A9; minor metabolism by CYP3A4. |
| Excretion | Renal: 60-80% unchanged; biliary/fecal: 10-20% |
| Half-life | 10-12 hours; prolonged in renal impairment |
| Protein binding | 25% bound to serum proteins |
| Volume of Distribution | 1.5-2.0 L/kg; indicates extensive tissue penetration |
| Bioavailability | Oral: 95-100% |
| Onset of Action | Oral: 1-2 hours |
| Duration of Action | 12 hours; sustained by post-antibiotic effect |
600 mg intravenously once daily or 600 mg orally once daily.
| Dosage form | TABLET |
| Renal impairment | CrCl 30–49 mL/min: 400 mg IV or oral once daily; CrCl 15–29 mL/min: 300 mg IV or oral once daily; CrCl <15 mL/min or hemodialysis: 200 mg IV or oral once daily. |
| Liver impairment | No dose adjustment required for mild or moderate hepatic impairment (Child-Pugh A or B); not studied in severe impairment (Child-Pugh C). |
| Pediatric use | Safety and efficacy not established in pediatric patients <18 years. |
| Geriatric use | No specific dose adjustment required; monitor renal function and adjust dose based on CrCl as per renal adjustment guidelines. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ZAGAM (ZAGAM).
| Breastfeeding | ZAGAM is excreted into human breast milk. The milk-to-plasma (M/P) ratio is not specifically reported for sparfloxacin, but for fluoroquinolones, it is typically around 0.8-1.5. Due to potential arthropathy in nursing infants, use during breastfeeding is not recommended; alternatives preferred. |
| Teratogenic Risk | Fluoroquinolones, including ZAGAM, are generally avoided in pregnancy due to arthropathy risk in immature animals; however, human data are limited. First trimester: no clear evidence of major malformations from limited cohort studies. Second and third trimesters: potential risk of fetal cartilage damage based on animal studies; avoid unless no safer alternative. |
■ FDA Black Box Warning
Fluoroquinolones, including sparfloxacin, have been associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in older patients (>60 years), patients taking corticosteroids, and patients with kidney, heart, or lung transplants.
| Serious Effects |
["Hypersensitivity to sparfloxacin or any fluoroquinolone","Known QT prolongation or concurrent use of QT-prolonging drugs","Uncorrected electrolyte disturbances (e.g., hypokalemia, hypomagnesemia)","History of tendon disorder related to fluoroquinolone use","Pregnancy and lactation (safety not established)"]
| Precautions | ["QT prolongation: sparfloxacin prolongs the QT interval; avoid in patients with known QT prolongation, electrolyte disturbances, or those taking other QT-prolonging drugs.","Photosensitivity: sparfloxacin is associated with significant phototoxicity; patients should avoid excessive sunlight and UV exposure.","Tendon damage: risk of tendinitis and tendon rupture, especially in older patients and those on corticosteroids.","Peripheral neuropathy: may cause irreversible neuropathy; discontinue if symptoms occur.","CNS effects: may cause dizziness, confusion, and increased risk of seizures; use caution in patients with CNS disorders."] |
Loading safety data…
| Fetal Monitoring | Monitor for maternal adverse effects: QT prolongation (ECG monitoring if other risk factors), photosensitivity, tendonitis, and gastrointestinal disturbances. Fetal monitoring: ultrasound for fetal growth and joint development if exposure occurs during second/third trimester. |
| Fertility Effects | Animal studies have not demonstrated impaired fertility. No human data on fertility impact; fluoroquinolones are not known to adversely affect human reproductive function. |